Dharmendra Ahluwalia
About
In The Last Decade
Dharmendra Ahluwalia
10 papers receiving 341 citations
Peers
Comparison fields: 5 of 49
- Cancer Research 254
- Molecular Biology 158
- Oncology 118
- Pulmonary and Respiratory Medicine 66
- Biomedical Engineering 59
Countries citing papers authored by Dharmendra Ahluwalia
This map shows the geographic impact of Dharmendra Ahluwalia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dharmendra Ahluwalia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dharmendra Ahluwalia more than expected).
Fields of papers citing papers by Dharmendra Ahluwalia
This network shows the impact of papers produced by Dharmendra Ahluwalia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dharmendra Ahluwalia. The network helps show where Dharmendra Ahluwalia may publish in the future.
Co-authorship network of co-authors of Dharmendra Ahluwalia
This figure shows the co-authorship network connecting the top 25 collaborators of Dharmendra Ahluwalia. A scholar is included among the top collaborators of Dharmendra Ahluwalia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dharmendra Ahluwalia. Dharmendra Ahluwalia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 21 | |
| 2 | 21 | |
| 3 | 45 | |
| 4 | Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models. | 20 |
| 5 | 1 | |
| 6 | 1 | |
| 7 | 86 | |
| 8 | 142 | |
| 9 | 15 | |
| 10 | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.